Wegovy (semaglutide) will no longer be available through Hims & Hers Health, as Novo Nordisk has ended its short-lived partnership.

There is always a challenging moment in every investor’s favorite stock and portfolio, especially when said businesses are ...

Earlier this week, the pharma giant publicly accused Hims & Hers of “deceptive” marketing that is putting patient safety at risk.

Hims & Hers (NYSE: HIMS) and UnitedHealth (NYSE: UNH) suffered huge stock price decreases that attracted investors looking to ...

Hims & Hers Health (HIMS -3.91%) is a telehealth company that offers personalized solutions for its customers. And demand has ...

Hims & Hers thrives with telehealth growth, strong subscriber base, and expanding products, despite challenges like ...

U.S. equities were mixed at midday with the markets focused on how U.S. tax and spending policy could impact the market.

Hims & Hers stands out for personalized, compounded medications and consistent margin expansion but faces rising risks tied ...

Senate To Begin Marathon Vote Series On Trump's "Big, Beautiful Bill" As GOP Eyes July 4 Deadline The Senate is set to kick off what's expected to be a marathon session Monday, after the chamber ...

Novo Nordisk is expanding access to its drug Wegovy through a new partnership with WeightWatchers, days after cutting ties with telehealth firm Hims & Hers. Starting July 1, WeightWatchers will ...

Should you invest $1,000 in Hims & Hers Health right now? Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Hims & Hers Health wasn’t ...

Hims & Hers extended its rally for the second day on Friday, adding 6.76 percent to close at $49.41 apiece after its chief ...